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2214-0247/Copyright ª 2015, TaiwanAbstract Spondyloarthritis presents clinical features, laboratory findings, and similar im-
ages, but their clinical manifestations reveal great heterogeneity in patients HLA-B*27 positive
and negative. This study compared the frequencies of the clinical manifestations in the pres-
ence and absence of HLA-B*27. From the 156 patients with clinical suspicion of spondyloarthri-
tis, 73 had a diagnosis of spondyloarthritis confirmed. The HLA-B*27 gene was identified by
polymerase chain-reaction sequence-specific oligonucleotide probe (PCR-SSOP). The Student
t test was used to calculate the values of mean and the Fisher’s exact test was used to
compare proportions. The values of odds ratio (OR) and confidence interval (CI) at 95% were
also calculated (p < 0.05). The spondyloarthritis found were: ankylosing spondylitis
(nZ 47, 64.4%), psoriatic spondyloarthritis (nZ 9, 12.3%), undifferentiated spondyloarthritisnto de Biologia Molecular, Faculdade de Medicina de Sa˜o Jose´ do Rio Preto e FAMERP, Avenida
do Rio Preto, SP, CEP 15090-000, Brazil.
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HLA-B*27 e Clinical signs in spondyloarthritis 73(n Z 9, 12.3%), enteropathic spondyloarthritis (n Z 6; 8.2%) and reactive spondyloarthritis
(n Z 2, 2.7%). Overall, 35 (47.9%) patients were HLA-B*27 positive and 38 (52.1%) were nega-
tive. This gene was associated with ankylosing spondylitis (OR: 5.37, 95% CI: 1.813e15.905,
p Z 0.003) but not with enteropathic spondyloarthritis (OR: 0.07, 95% CI: 0.003e1.301,
p Z 0.025). The sacroiliitis was associated with HLA-B*27 positive (OR: 10.552, 95% CI:
1.260e88.256, p Z 0.014) and intestinal injury with HLA-B*27 negative (OR: 0.195, 95% CI:
0.038e0.978, p Z 0.048). The image signals sacroiliitis were associated with the HLA-B*27
gene while intestinal involvement was not associated with this gene.
Copyright ª 2015, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Spondyloarthritis is a group of diseases with common clin-
ical, laboratory, and image findings. In this group fall
ankylosing spondylitis, psoriatic spondyloarthritis, enter-
opathic spondyloarthritis (spondyloarthritis associated with
Crohn’s disease or ulcerative colitis), reactive spondyloar-
thritis, and undifferentiated spondyloarthritis.1 These dis-
eases are characterized by frequent inflammatory joint
involvement of the sacroiliac joints (sacroiliitis) and/or
peripheral joints, predominantly oligoarthritis of large
joints of the lower limbs. Ocular inflammatory lesions
(uveitis), bowel (colitis nonspecific), or enthesitis (heel
enthesitis) are additional findings in spondyloarthritis.
Specific manifestations for each of the diseases belonging
to the spondyloarthritis group are also frequently re-
ported.1 Furthermore, spondyloarthritis is commonly asso-
ciated with the HLA-B*27 gene, but the prevalence of this
gene varies with each specific disease.1e3
Different studies have analyzed the clinical manifesta-
tions of spondyloarthritis in patients with and without HLA-
B*27, but the results revealed great heterogeneity. In a
previous study, it was observed that the presence of this gene
in patients with back pain increases the risk of sacroiliitis by
50%.4 However, assessing the involvement of the hip joint in
patientswith spondyloarthritis, Burki and colleagues5 did not
find association between this involvement and the presence
of HLA-B*27. Also, another study reported no association
between this gene and acute anterior uveitis in patients with
spondyloarthritis.6 However, in another recent study, the
authors reported that the occurrence of uveitis in patients
with spondyloarthritis is an event common in patients car-
rying the HLA-B*27 gene.7 These data demonstrate the
disagreement in the literature on the relationship between
the clinical manifestations of spondyloarthritis and the HLA-
B*27 gene. The aim of this study was to compare the fre-
quencies of the main clinical signs of spondyloarthritis in the
presence and absence of the HLA-B*27 gene.Materials and methods
Ethical consideration
This cross-sectional study was approved by the Research
Ethics Committee of Medical School of Sa˜o Jose´ do Rio Preto(FAMERP), Sa˜o Jose´ do Rio Preto (Case 055/2011) and each
participant, after receiving all the information about the
study objectives as well as on the procedures performed,
signed the consent form.
Composition of the study groups
From June 2007 to May 2010, 156 patients with clinical
suspicion of spondyloarthritis were referred to the Outpa-
tient Clinic of Rheumatology from the Regional Medical
Faculty Foundation (FUNFARME). All of them were investi-
gated for the presence or absence of the HLA-B*27 gene at
the Immunogenetics Laboratory of the Molecular Biology
Department from Medical School of Sa˜o Jose´ do Rio Preto
(FAMERP). Overall, 73 patients had a clinical diagnosis of
spondyloarthritis confirmed according to the criteria of the
European Study Group Spondyloarthropathy (ESSG) used at
the time.8 Clinical information was obtained from the
medical records of patients.
Blood sampling and genomic DNA extraction
A sample of 5 mL of peripheral blood was collected in tubes
with EDTA from each individual by venipuncture. The
genomic DNA was extracted from the white blood cells
using a commercial kit (PureLink, Invitrogen, Carlsbad,
CA, USA).
HLA-B*27 genotyping
The HLA-B*27 genotyping was performed by polymerase
chain reaction-specific sequence oligonucleotide (PCR-SSO)
in a low resolution system (One Lambda INC, Canoga Park,
CA, USA) with Luminex technology. The manufacturer’s
recommendations were strictly followed.
Statistical analysis
The data were compared using Fisher’s exact test (Graph-
Pad Instat version 3.06, GraphPad Software, Inc., La Jolla,
CA, USA). The mean values for age were calculated by the
Student t test. Odds ratio (OR) and confidence interval (CI)
of 95% values were also calculated. A p value  0.05 was
considered significant.
Table 1 Frequencies of spondyloarthritis according to gender in 73 Brazilian patients.
Spondyloarthritis Male
n (%)
Female
n (%)
OR (95% CI) p
Mean age  SD (y) 49.4  12.7 46.2  10.7 0.320a
Median age (range) 47.5 (20e80) 48.5 (20e62)
Ankylosing spondylitis (n Z 47; 64.4%) 34 (64.2) 13 (65.0) 0.936 (0.328e2.829) 1.000b
Psoriatic spondyloarthritis (n Z 9; 12.3%) 7 (13.2) 2 (10.0) 1.370 (0.259e7.229) 1.000b
Undifferentiated spondyloarthritis (n Z 9; 12.3%) 5 (9.4) 4 (20.0) 0.416 (0.099e1.744) 0.246b
Enteropathic spondyloarthritis (n Z 6; 8.2%) 6 (11.3) 0 (0.0) 5.611 (0.301e10.380) 0.179b
Reactive spondyloarthritis (n Z 2; 2.7%) 1 (1.9) 1 (5.0) 0.365 (0.021-6.141) 0.475b
Total (n Z 73) 53 (100) 20 (100)
OR Z odds ratio; SD Z standard deviation.
a Calculated by Student t test.
b Calculated by Fisher’s exact test.
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Of the 73 selected patients, 53 (72.6%) were male and 20
(27.4%) female. The mean age for the whole casuistic was
48.7  12.2 years and did not differ between the genders
(p Z 0.320). The median for the whole casuistic was 48
years, ranging from 20 years to 80 years. The distribution of
the five spondyloarthritis between genders did not present
statistically significant differences (Table 1).
Table 2 shows the frequencies of gender and the spon-
dyloarthritis according to the presence (n Z 35, 47.9%) or
absence (n Z 38, 52.1%) of the HLA-B*27 gene. The HLA-
B*27 gene was more frequent in males (30/53; 56.6%) than
in females (5/20; 25.0%). Ankylosing spondylitis was more
frequent in males who were HLA-B*27 positive (26/30;
86.6%) than in females who were HLA-B*27 positive (3/5;
60.0%; OR: 10.833, 95% CI: 2.382e49.261, p Z 0.001; data
not shown). The values of OR highlight the importance of
the presence of this gene as a risk factor for ankylosing
spondylitis in males.
Table 3 shows the frequencies of the clinical signs in
patients with and without the HLA-B*27 gene. The mean
age at onset of symptoms was 39.1  11.7 years and did not
differ between the genders (p Z 0.905). A strong associa-
tion between bilateral sacroiliitis and the HLA-B*27 geneTable 2 Frequencies of gender, and spondyloarthritis and HLA-
Spondyloarthritis HLA-B*27 (þ)
n (%)
Mean age  SD (y) 48.5  13.5
Sex
Male 30 (85.7)
Female 5 (14.3)
Ankylosing spondylitis 29 (82.8)
Psoriatic spondyloarthritis 2 (5.7)
Undifferentiated spondyloarthritis 3 (8.6)
Enteropathic spondyloarthritis 0 (0.0)
Reactive spondyloarthritis 1 (2.9)
Total (n Z 73) 35 (100)
þ Z presence;  Z absence.
* p < 0.05 indicates significance.
a Calculated by Student t test.
b Calculated by Fisher’s exact test.was observed for ankylosing spondylitis in comparison to
other spondyloarthritis (OR: 5.294, 95% CI: 1.474e19.018,
p Z 0.009; data not shown in table). The values of OR
highlight the importance of the presence and absence of
the HLA-B*27 gene with the clinical signs of radiological
sacroiliitis (p Z 0.014) and intestinal involvement
(p Z 0.048) among patients suffering from different spon-
dyloarthritis, respectively.Discussion
The aim of this study was to compare the frequencies of the
main clinical signals used as criteria for the diagnosis of
spondyloarthritis according to the ESSG, in patients with and
without HLA-B*27. A sample of patients from the north-
western region of Sa˜o Paulo, Brazil characterized by the in-
fluence of a European background were analyzed.9 The
criteria of the ESSG were adopted for the diagnosis of the
spondyloarthritis investigated in this study, since they include
clinical, laboratory, imaging, and the presence of HLA-B*27.
These criteria are considered indicators of good sensitivity
and specificity in the diagnosis of this group of diseases.8
The HLA genotyping method used in this study is uni-
versally recognized as a good tool for characterization ofB*27 in 73 Brazilian patients.
HLA-B*27 ()
n (%)
OR (95% CI) p
48.8  10.9 0.909a
23 (60.5) 3.91 (1.240e12.345) 0.019b,*
15 (39.5)
18 (47.4) 5.37 (1.813e15.905) 0.003b,*
7 (18.4) 0.26 (0.051e1.393) 0.155b
6 (15.8) 0.50 (0.114e2.175) 0.482b
6 (15.8) 0.07 (0.003e1.301) 0.025b,*
1 (2.6) 1.00 (0.065e18.100) 1.000b
38 (100)
Table 3 Main clinical signs in 73 Brazilian patients with different spondyloarthritis according to positivity for the HLA-B*27
gene.
Main clinical signs n HLA-B*27 (þ)
n (%)
HLA-B*27 ()
n (%)
OR (95%CI) p
Axial pain 60 31 (51.7) 29 (48.3) 2.405 (0.667e8.671) 0.226
Radiological sacroiliitis 63 34 (53.9) 29 (46.1) 10.552 (1.260e88.256) 0.014*
Synovitis 27 12 (44.4) 15 (55.6) 0.800 (0.308e2.078) 0.808
Family history 4 3 (75.0) 1 (25.0) 3.469 (0.343e35.039) 0.344
Psoriasis 10 2 (20.0) 8 (80.0) 0.227 (0.044e1.156) 0.088
Intestinal involvement 11 2 (18.2) 9 (81.8) 0.195 (0.038e0.978) 0.048*
Pain in the buttocks 10 3 (30.0) 7 (70.0) 0.415 (0.098e1.753) 0.312
Enthesitis 4 3 (75.0) 1 (25.0) 3.469 (0.343e35.039) 0.344
Diarrhea 1 mo before 1 0 (0.0) 1 (100) 0.352 (0.013e8.938) 1.000
Urethritis 1 1 (100) 0 (0.0) 3.438 (0.131e84.990) 0.475
* p < 0.05 indicates significance, calculated by Fisher’s exact test.
þ Z presence; , absence.
HLA-B*27 e Clinical signs in spondyloarthritis 75HLA polymorphisms. It has been extensively used for
matching transplant recipients and donors and for genomic
wide association studies. It allows the identification of the
HLA-B*27 alleles and the determination of homozygous and
heterozygous genotypes with a better level of resolution in
comparison with serological methods used in the past,
which presented some limitations.10 Recently, we used this
method to determine the frequencies of HLA Class I and
Class II genes among voluntary bone marrow donors from
the northwestern region of Sa˜o Paulo.11
The HLA-B*27 gene presented a high frequency in our
casuistic, but it was prevalent among those suffering from
ankylosing spondylitis. Also, it was prevalent in male pa-
tients in comparison to female patients. Despite these
differences, there were no statistically significant differ-
ences between genders with respect to the frequencies of
the six spondyloarthritis analyzed in this study. These data
agree with those published by the Ibero-American Registry
of Spondyloarthritis (RESPONDIA) Study Group for Brazilian
patients and suggest that the frequencies of spondyloar-
thritis diagnosed in the northwest of Sa˜o Paulo did not
differ from those reported for other regions of Brazil.12
These observations highlight the clinical importance of
the HLA-B*27 gene as an important immunogenetic risk
factor for spondyloarthritis.
The presence of spondyloarthritis was approximately
three times higher in men than in women and the average
age of onset of symptoms did not differ between the gen-
ders. The most frequent spondyloarthritis was ankylosing
spondylitis, followed by psoriatic spondyloarthritis, and
undifferentiated spondyloarthritis. The enteropathic spon-
dyloarthritis and reactive arthritis appeared less
frequently. These data are in agreement with those re-
ported by Gallinaro and colleagues12 for Brazilian patients.
In view of these observations, it can be assumed at least in
principle that if there are other selective genetic or envi-
ronmental factors in nature acting in the genesis of this
group of diseases in the region where this study was con-
ducted, they do not seem to modify the frequency of
spondyloarthritis commonly diagnosed in the population.
Ankylosing spondylitis, as expected, was positively
associated with the HLA-B*27 gene. The molecular basesunderlying this association are not fully understood. How-
ever, studies with transgenic animal models show that the
HLA-B*27 gene plays an important role in the genesis of
ankylosing spondylitis, but due to the complexity of the
disease, this gene is the only one among several genes that
determines predisposition and phenotypic variations of this
disease.13 It is possible that incorrect folding and dimer-
ization of the a chain of HLA-B27 glycoprotein in the
endoplasmic reticulum, allied to the high expression of
interleukin-23 (IL-23) the polymorphisms of its receptor (IL-
23R) contribute to susceptibility to ankylosing
spondylitis.3,14e16 These observations support the view that
ankylosing spondylitis is a complex disease and although its
clinical variability can be influenced by other genes, the
HLA-B*27 gene occupies a prominent position as a marker of
susceptibility to this form of spondyloarthritis.17,18
The enteropathic spondyloarthritis was negatively asso-
ciated with the HLA-B*27 gene, including those patients
with manifestations of sacroiliitis. These observations
disagree with a previous study18 but are consistent with
others that have shown the absence of the HLA-B*27 gene in
the majority of patients with inflammatory bowel disease
associated with spondyloarthritis.19e22 The reasons for this
negative association are not fully understood, but it is
possible that ethnicity contributes to the different clinical
manifestations of spondyloarthritis in this Brazilian
casuistic.23
In fact, the population of the northwestern region of Sa˜o
Paulo has a strong Italian, Spanish, Portuguese, and Arabic
genetic background, while the sample of Protzer and col-
leagues18 is primarily of German origin. Furthermore, it is
possible that the absence of the HLA-B*27 gene exerts a less
modulator effect on the genesis of sacroiliitis in the
enteropathic spondyloarthritis and that other genes which
contribute to modulation of the autoimmune response in
this form of spondyloarthritis.24
This study noted that radiological sacroiliitis is associ-
ated with the HLA-B*27 gene independent of the type of the
spondyloarthritis, but it was stronger for patients with
ankylosing spondylitis. This association is explained at least
in part by the strong influence of this gene in the patho-
genesis of ankylosing spondylitis. The observation that the
76 R.A. de Toledo et al.severity and the number of sacroiliac lesions correlate
strongly with the HLA-B*27 gene substantiate the proposi-
tion that ankylosing spondylitis begins in the sacroiliac
joints and progresses to the spine.17 However, it is not clear
how the HLA-B*27 gene contributes to bilateral sacroiliitis
in other spondyloarthritis.3,17 In fact, a minor proportion of
patients with other spondyloarthritis carrying bilateral
sacroiliitis and the HLA-B*27 gene were observed in this
study. As the direct effect of this gene on the origin and
evolution of sacroiliitis still remains unclear, this topic de-
serves much more investigation.25
This study also observed a marginal association between
intestinal involvement and the absence of the HLA-B*27
gene and these data confirm observations previously re-
ported.22,26 It is possible that this negative association ob-
scures the radiological manifestations in patients, who
displaying other genetic predisposition factors, have sac-
roiliitis and intestinal injury even in the absence of HLA-
B*27. Half of the patients analyzed here, carrying the
enteropathic form of the disease, presented clinical and
radiological signs of sacroiliitis, but they were HLA-B*27
negative. This observation agrees with the proposition that
the presence of sacroiliitis in enteropathic spondyloarthritis
is an isolated phenomenon and not related to the HLA-B*27
gene.22,26
All of the six patients with enteropathic spondyloarthritis
analyzed in this study first developed inflammatory bowel
disease and then had joint involvement. Furthermore, of the
11 patients with intestinal involvement, regardless of diag-
nosis, nine were HLA-B*27 negative. The reasons for this
sequence of events are not fully understood, but it is possible
that the HLA-B*27 gene has a lower effect in modulating the
intestinal autoimmune response in comparison with that
affecting the joints, mainly the axial spine.22,26
The data presented here must be viewed with caution
due to the small number of patients enrolled and therefore
these results should be taken as preliminary. Similar studies
enrolling greater sample sizes and composed of other
ethnic and mixed casuistic in Brazil may contribute to
confirming our findings.
Conclusion
In conclusion, we observed that the HLA-B*27 gene was
more prevalent in patients with ankylosing spondylitis, but
not in those with enteropathic spondyloarthritis. The image
signals of sacroiliitis were associated with the presence of
this gene, whereas the intestinal involvement was associ-
ated with its absence.
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